PDF(Pubmed)
Abstract：
Glutathione S-transferase theta 1 (GSTT1) enzyme plays a key role in the neutralization of electrophilic compounds such as carcinogens. Herein, we aimed to evaluate GSTT1 deletion polymorphism and susceptibility to head and neck carcinoma (HNC) according to 107 articles in a systematic review with five analyses. The databases of PubMed/Medline, Web of Science, Scopus, and Cochrane Library from the beginning of each database until June 21, 2023, with no restrictions to identify pertinent articles. The RevMan 5.3 software was used to calculate the effect sizes, which were displayed as the odds ratio (OR) along with a 95% confidence interval (CI). Both the publication bias and sensitivity analyses were performed using the CMA 3.0 software. A trial sequential analysis (TSA) was conducted. Of the 1966 records retrieved from four databases, 107 articles were included in the analysis. The combined analysis revealed that the pooled OR was 1.28 (95% CI: 1.14 to 1.44; p-value < 0.0001). The pooled OR was highest in mixed ethnicity. Nasopharyngeal cancer had the highest OR (1.84), followed by oral cancer (OR = 1.20), and laryngeal cancer (OR = 1.17). Studies with less than 200 samples had a higher OR compared to those with 200 or more samples. The studies with a quality score of 7 or more had a higher OR compared to those with a score of less than 7. When both age and sex are considered, while the OR of 1.42 is significant, the high heterogeneity suggests caution in interpreting these results. There is no evidence of publication bias. TSA reported that the study does not have sufficient statistical power. This comprehensive meta-analysis revealed a significant association between the GSTT1 null genotype and an increased risk of HNC, with variations based on factors such as ethnicity, cancer type, sample size, control source, and quality score.
摘要：
谷胱甘肽S-转移酶θ1(GSTT1)酶在中和亲电化合物如致癌物中起关键作用。在这里，我们的目的是评估GSTT1缺失多态性和对头颈部癌(HNC)的易感性,根据系统评价的107篇文章,包括5项分析.PubMed/Medline的数据库，WebofScience,Scopus,和Cochrane图书馆从每个数据库的开始到2023年6月21日，没有任何限制来识别相关文章。RevMan5.3软件用于计算效果大小，显示为比值比(OR)和95%置信区间(CI)。发表偏倚和敏感性分析均使用CMA3.0软件进行。进行试验序贯分析(TSA)。在从四个数据库检索的1966年记录中，107篇文章被纳入分析。合并分析显示，合并OR为1.28（95％CI：1.14至1.44；p值<0.0001）。合并OR在混合种族中最高。鼻咽癌的OR值最高(1.84),其次是口腔癌（OR=1.20），和喉癌（OR=1.17）。与具有200个或更多样品的研究相比,具有少于200个样品的研究具有更高的OR。质量评分为7或更高的研究与评分小于7的研究相比具有更高的OR。当考虑到年龄和性别时，虽然1.42的OR是显著的，高度异质性表明在解释这些结果时应谨慎。没有发表偏倚的证据。TSA报告说，该研究没有足够的统计能力。这项全面的荟萃分析揭示了GSTT1无效基因型与HNC风险增加之间的显着关联。基于种族等因素的变化，癌症类型,样本量,控制源，和质量得分。
